Eintrag weiter verarbeiten
Effect of Ga-68 PSMA-11 PET on management in patients with recurrent prostate cancer.
Gespeichert in:
| Zeitschriftentitel: | Journal of Clinical Oncology |
|---|---|
| Personen und Körperschaften: | , , , , , , , , , , |
| In: | Journal of Clinical Oncology, 35, 2017, 15_suppl, S. 5057-5057 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
American Society of Clinical Oncology (ASCO)
|
| Schlagwörter: |
| author_facet |
Hope, Tom Aggarwal, Rahul Raj Greene, Kirsten L Chee, Bryant Tao, Dora Feng, Felix Yi-Chung Chang, Albert Cooperberg, Matthew R. Ryan, Charles J. Small, Eric Jay Carroll, Peter Hope, Tom Aggarwal, Rahul Raj Greene, Kirsten L Chee, Bryant Tao, Dora Feng, Felix Yi-Chung Chang, Albert Cooperberg, Matthew R. Ryan, Charles J. Small, Eric Jay Carroll, Peter |
|---|---|
| author |
Hope, Tom Aggarwal, Rahul Raj Greene, Kirsten L Chee, Bryant Tao, Dora Feng, Felix Yi-Chung Chang, Albert Cooperberg, Matthew R. Ryan, Charles J. Small, Eric Jay Carroll, Peter |
| spellingShingle |
Hope, Tom Aggarwal, Rahul Raj Greene, Kirsten L Chee, Bryant Tao, Dora Feng, Felix Yi-Chung Chang, Albert Cooperberg, Matthew R. Ryan, Charles J. Small, Eric Jay Carroll, Peter Journal of Clinical Oncology Effect of Ga-68 PSMA-11 PET on management in patients with recurrent prostate cancer. Cancer Research Oncology |
| author_sort |
hope, tom |
| spelling |
Hope, Tom Aggarwal, Rahul Raj Greene, Kirsten L Chee, Bryant Tao, Dora Feng, Felix Yi-Chung Chang, Albert Cooperberg, Matthew R. Ryan, Charles J. Small, Eric Jay Carroll, Peter 0732-183X 1527-7755 American Society of Clinical Oncology (ASCO) Cancer Research Oncology http://dx.doi.org/10.1200/jco.2017.35.15_suppl.5057 <jats:p> 5057 </jats:p><jats:p> Background: PET imaging of prostate specific membrane antigen (PSMA) has been shown to have a higher sensitivity and specificity compared to conventional imaging. The objective was to evaluate the impact of PSMA PET on the management of prostate cancer patients with biochemical recurrence following local therapy. Methods: In our initial Ga-68-PSMA-11 PET protocol (NCT02611882), 150 patients with biochemical recurrence were imaged. 63 patients were imaged using PET/CT (GE Discovery VCT) and 63 patients using PET/MRI (GE Signa 3.0T PET/MRI). 110 patients received Lasix injections. Referring clinicians filled out a pretreatment management form and a management form based on the imaging results. Changes in management were graded as major, minor, no change or unknown based upon the responses. Results: We received both pre and post imaging forms in 126 patients, for an 84% response rate. The average PSA in the population was 5.9 ± 5.4 ng/mL with an average doubling time of 9.7 ± 11.0 months, and 60 patients had a PSA of less than 2.0 at the time of imaging. The average time between prior treatment and imaging (RP and/or radiation) was 5.3 ± 5.4 years, with 46 patients imaged within two years of their most recent treatment. 43 patients had a prior prostatectomy, 41 prior radiation, and 33 patients had both. 103 patients (82%) had disease localized on PSMA imaging. Of the 126 patients, 67 (53%) of the imaging studies resulted in a major change in management. The most common major change was converting from active surveillance to radiation therapy (15 patients, 12%), changing from ADT to radiation therapy (16 patients, 13%), and converting from radiation therapy to either active surveillance (6 patients, 5%) or to ADT alone (3 patients, 2%). 10 patients (8%) had a minor change, 42 patients (33%) had no change, and 7 patients (6%) had an unknown change in management. Conclusions: The results of our surveys demonstrate a substantial impact of PSMA PET on the intended patient management. The majority of changes involved converting a targeted therapy to systemic treatment or systemic treatment to a targeted therapy. Prospective studies are warranted to determine whether directed treatment towards PSMA-avid lesions affects long-term disease outcomes. Clinical trial information: NCT02611882. </jats:p> Effect of Ga-68 PSMA-11 PET on management in patients with recurrent prostate cancer. Journal of Clinical Oncology |
| doi_str_mv |
10.1200/jco.2017.35.15_suppl.5057 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAxNy4zNS4xNV9zdXBwbC41MDU3 |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAxNy4zNS4xNV9zdXBwbC41MDU3 |
| institution |
DE-105 DE-14 DE-Ch1 DE-L229 DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 |
| imprint |
American Society of Clinical Oncology (ASCO), 2017 |
| imprint_str_mv |
American Society of Clinical Oncology (ASCO), 2017 |
| issn |
0732-183X 1527-7755 |
| issn_str_mv |
0732-183X 1527-7755 |
| language |
English |
| mega_collection |
American Society of Clinical Oncology (ASCO) (CrossRef) |
| match_str |
hope2017effectofga68psma11petonmanagementinpatientswithrecurrentprostatecancer |
| publishDateSort |
2017 |
| publisher |
American Society of Clinical Oncology (ASCO) |
| recordtype |
ai |
| record_format |
ai |
| series |
Journal of Clinical Oncology |
| source_id |
49 |
| title |
Effect of Ga-68 PSMA-11 PET on management in patients with recurrent prostate cancer. |
| title_unstemmed |
Effect of Ga-68 PSMA-11 PET on management in patients with recurrent prostate cancer. |
| title_full |
Effect of Ga-68 PSMA-11 PET on management in patients with recurrent prostate cancer. |
| title_fullStr |
Effect of Ga-68 PSMA-11 PET on management in patients with recurrent prostate cancer. |
| title_full_unstemmed |
Effect of Ga-68 PSMA-11 PET on management in patients with recurrent prostate cancer. |
| title_short |
Effect of Ga-68 PSMA-11 PET on management in patients with recurrent prostate cancer. |
| title_sort |
effect of ga-68 psma-11 pet on management in patients with recurrent prostate cancer. |
| topic |
Cancer Research Oncology |
| url |
http://dx.doi.org/10.1200/jco.2017.35.15_suppl.5057 |
| publishDate |
2017 |
| physical |
5057-5057 |
| description |
<jats:p> 5057 </jats:p><jats:p> Background: PET imaging of prostate specific membrane antigen (PSMA) has been shown to have a higher sensitivity and specificity compared to conventional imaging. The objective was to evaluate the impact of PSMA PET on the management of prostate cancer patients with biochemical recurrence following local therapy. Methods: In our initial Ga-68-PSMA-11 PET protocol (NCT02611882), 150 patients with biochemical recurrence were imaged. 63 patients were imaged using PET/CT (GE Discovery VCT) and 63 patients using PET/MRI (GE Signa 3.0T PET/MRI). 110 patients received Lasix injections. Referring clinicians filled out a pretreatment management form and a management form based on the imaging results. Changes in management were graded as major, minor, no change or unknown based upon the responses. Results: We received both pre and post imaging forms in 126 patients, for an 84% response rate. The average PSA in the population was 5.9 ± 5.4 ng/mL with an average doubling time of 9.7 ± 11.0 months, and 60 patients had a PSA of less than 2.0 at the time of imaging. The average time between prior treatment and imaging (RP and/or radiation) was 5.3 ± 5.4 years, with 46 patients imaged within two years of their most recent treatment. 43 patients had a prior prostatectomy, 41 prior radiation, and 33 patients had both. 103 patients (82%) had disease localized on PSMA imaging. Of the 126 patients, 67 (53%) of the imaging studies resulted in a major change in management. The most common major change was converting from active surveillance to radiation therapy (15 patients, 12%), changing from ADT to radiation therapy (16 patients, 13%), and converting from radiation therapy to either active surveillance (6 patients, 5%) or to ADT alone (3 patients, 2%). 10 patients (8%) had a minor change, 42 patients (33%) had no change, and 7 patients (6%) had an unknown change in management. Conclusions: The results of our surveys demonstrate a substantial impact of PSMA PET on the intended patient management. The majority of changes involved converting a targeted therapy to systemic treatment or systemic treatment to a targeted therapy. Prospective studies are warranted to determine whether directed treatment towards PSMA-avid lesions affects long-term disease outcomes. Clinical trial information: NCT02611882. </jats:p> |
| container_issue |
15_suppl |
| container_start_page |
5057 |
| container_title |
Journal of Clinical Oncology |
| container_volume |
35 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792326363692138496 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T12:20:19.191Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Effect+of+Ga-68+PSMA-11+PET+on+management+in+patients+with+recurrent+prostate+cancer.&rft.date=2017-05-20&genre=article&issn=1527-7755&volume=35&issue=15_suppl&spage=5057&epage=5057&pages=5057-5057&jtitle=Journal+of+Clinical+Oncology&atitle=Effect+of+Ga-68+PSMA-11+PET+on+management+in+patients+with+recurrent+prostate+cancer.&aulast=Carroll&aufirst=Peter&rft_id=info%3Adoi%2F10.1200%2Fjco.2017.35.15_suppl.5057&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792326363692138496 |
| author | Hope, Tom, Aggarwal, Rahul Raj, Greene, Kirsten L, Chee, Bryant, Tao, Dora, Feng, Felix Yi-Chung, Chang, Albert, Cooperberg, Matthew R., Ryan, Charles J., Small, Eric Jay, Carroll, Peter |
| author_facet | Hope, Tom, Aggarwal, Rahul Raj, Greene, Kirsten L, Chee, Bryant, Tao, Dora, Feng, Felix Yi-Chung, Chang, Albert, Cooperberg, Matthew R., Ryan, Charles J., Small, Eric Jay, Carroll, Peter, Hope, Tom, Aggarwal, Rahul Raj, Greene, Kirsten L, Chee, Bryant, Tao, Dora, Feng, Felix Yi-Chung, Chang, Albert, Cooperberg, Matthew R., Ryan, Charles J., Small, Eric Jay, Carroll, Peter |
| author_sort | hope, tom |
| container_issue | 15_suppl |
| container_start_page | 5057 |
| container_title | Journal of Clinical Oncology |
| container_volume | 35 |
| description | <jats:p> 5057 </jats:p><jats:p> Background: PET imaging of prostate specific membrane antigen (PSMA) has been shown to have a higher sensitivity and specificity compared to conventional imaging. The objective was to evaluate the impact of PSMA PET on the management of prostate cancer patients with biochemical recurrence following local therapy. Methods: In our initial Ga-68-PSMA-11 PET protocol (NCT02611882), 150 patients with biochemical recurrence were imaged. 63 patients were imaged using PET/CT (GE Discovery VCT) and 63 patients using PET/MRI (GE Signa 3.0T PET/MRI). 110 patients received Lasix injections. Referring clinicians filled out a pretreatment management form and a management form based on the imaging results. Changes in management were graded as major, minor, no change or unknown based upon the responses. Results: We received both pre and post imaging forms in 126 patients, for an 84% response rate. The average PSA in the population was 5.9 ± 5.4 ng/mL with an average doubling time of 9.7 ± 11.0 months, and 60 patients had a PSA of less than 2.0 at the time of imaging. The average time between prior treatment and imaging (RP and/or radiation) was 5.3 ± 5.4 years, with 46 patients imaged within two years of their most recent treatment. 43 patients had a prior prostatectomy, 41 prior radiation, and 33 patients had both. 103 patients (82%) had disease localized on PSMA imaging. Of the 126 patients, 67 (53%) of the imaging studies resulted in a major change in management. The most common major change was converting from active surveillance to radiation therapy (15 patients, 12%), changing from ADT to radiation therapy (16 patients, 13%), and converting from radiation therapy to either active surveillance (6 patients, 5%) or to ADT alone (3 patients, 2%). 10 patients (8%) had a minor change, 42 patients (33%) had no change, and 7 patients (6%) had an unknown change in management. Conclusions: The results of our surveys demonstrate a substantial impact of PSMA PET on the intended patient management. The majority of changes involved converting a targeted therapy to systemic treatment or systemic treatment to a targeted therapy. Prospective studies are warranted to determine whether directed treatment towards PSMA-avid lesions affects long-term disease outcomes. Clinical trial information: NCT02611882. </jats:p> |
| doi_str_mv | 10.1200/jco.2017.35.15_suppl.5057 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAxNy4zNS4xNV9zdXBwbC41MDU3 |
| imprint | American Society of Clinical Oncology (ASCO), 2017 |
| imprint_str_mv | American Society of Clinical Oncology (ASCO), 2017 |
| institution | DE-105, DE-14, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1 |
| issn | 0732-183X, 1527-7755 |
| issn_str_mv | 0732-183X, 1527-7755 |
| language | English |
| last_indexed | 2024-03-01T12:20:19.191Z |
| match_str | hope2017effectofga68psma11petonmanagementinpatientswithrecurrentprostatecancer |
| mega_collection | American Society of Clinical Oncology (ASCO) (CrossRef) |
| physical | 5057-5057 |
| publishDate | 2017 |
| publishDateSort | 2017 |
| publisher | American Society of Clinical Oncology (ASCO) |
| record_format | ai |
| recordtype | ai |
| series | Journal of Clinical Oncology |
| source_id | 49 |
| spelling | Hope, Tom Aggarwal, Rahul Raj Greene, Kirsten L Chee, Bryant Tao, Dora Feng, Felix Yi-Chung Chang, Albert Cooperberg, Matthew R. Ryan, Charles J. Small, Eric Jay Carroll, Peter 0732-183X 1527-7755 American Society of Clinical Oncology (ASCO) Cancer Research Oncology http://dx.doi.org/10.1200/jco.2017.35.15_suppl.5057 <jats:p> 5057 </jats:p><jats:p> Background: PET imaging of prostate specific membrane antigen (PSMA) has been shown to have a higher sensitivity and specificity compared to conventional imaging. The objective was to evaluate the impact of PSMA PET on the management of prostate cancer patients with biochemical recurrence following local therapy. Methods: In our initial Ga-68-PSMA-11 PET protocol (NCT02611882), 150 patients with biochemical recurrence were imaged. 63 patients were imaged using PET/CT (GE Discovery VCT) and 63 patients using PET/MRI (GE Signa 3.0T PET/MRI). 110 patients received Lasix injections. Referring clinicians filled out a pretreatment management form and a management form based on the imaging results. Changes in management were graded as major, minor, no change or unknown based upon the responses. Results: We received both pre and post imaging forms in 126 patients, for an 84% response rate. The average PSA in the population was 5.9 ± 5.4 ng/mL with an average doubling time of 9.7 ± 11.0 months, and 60 patients had a PSA of less than 2.0 at the time of imaging. The average time between prior treatment and imaging (RP and/or radiation) was 5.3 ± 5.4 years, with 46 patients imaged within two years of their most recent treatment. 43 patients had a prior prostatectomy, 41 prior radiation, and 33 patients had both. 103 patients (82%) had disease localized on PSMA imaging. Of the 126 patients, 67 (53%) of the imaging studies resulted in a major change in management. The most common major change was converting from active surveillance to radiation therapy (15 patients, 12%), changing from ADT to radiation therapy (16 patients, 13%), and converting from radiation therapy to either active surveillance (6 patients, 5%) or to ADT alone (3 patients, 2%). 10 patients (8%) had a minor change, 42 patients (33%) had no change, and 7 patients (6%) had an unknown change in management. Conclusions: The results of our surveys demonstrate a substantial impact of PSMA PET on the intended patient management. The majority of changes involved converting a targeted therapy to systemic treatment or systemic treatment to a targeted therapy. Prospective studies are warranted to determine whether directed treatment towards PSMA-avid lesions affects long-term disease outcomes. Clinical trial information: NCT02611882. </jats:p> Effect of Ga-68 PSMA-11 PET on management in patients with recurrent prostate cancer. Journal of Clinical Oncology |
| spellingShingle | Hope, Tom, Aggarwal, Rahul Raj, Greene, Kirsten L, Chee, Bryant, Tao, Dora, Feng, Felix Yi-Chung, Chang, Albert, Cooperberg, Matthew R., Ryan, Charles J., Small, Eric Jay, Carroll, Peter, Journal of Clinical Oncology, Effect of Ga-68 PSMA-11 PET on management in patients with recurrent prostate cancer., Cancer Research, Oncology |
| title | Effect of Ga-68 PSMA-11 PET on management in patients with recurrent prostate cancer. |
| title_full | Effect of Ga-68 PSMA-11 PET on management in patients with recurrent prostate cancer. |
| title_fullStr | Effect of Ga-68 PSMA-11 PET on management in patients with recurrent prostate cancer. |
| title_full_unstemmed | Effect of Ga-68 PSMA-11 PET on management in patients with recurrent prostate cancer. |
| title_short | Effect of Ga-68 PSMA-11 PET on management in patients with recurrent prostate cancer. |
| title_sort | effect of ga-68 psma-11 pet on management in patients with recurrent prostate cancer. |
| title_unstemmed | Effect of Ga-68 PSMA-11 PET on management in patients with recurrent prostate cancer. |
| topic | Cancer Research, Oncology |
| url | http://dx.doi.org/10.1200/jco.2017.35.15_suppl.5057 |